ENZALUTAMIDE-INDUCED HEART FAILURE WITH REDUCED EJECTION FRACTION
Abstract
Prostate cancer is the second most common malignancy in men and the second leading cause of cancer death. Patients unfit for surgery, with locally advanced or metastatic disease, require androgen-deprivation therapy.
In the past decade, enzalutamide and abiraterone were established in prostate cancer treatment. Their safety profile and clinical evidence showed a significant possibility of cardiovascular complications. Heart failure is more common in patients treated with abiraterone. We report a case of a patient with heart failure induced by enzalutamide. In the review of the literature, enzalutmaide-induced heart failure was encountered in only two cases.
Further research on the influence of novel anti-androgen therapy on the cardiovascular system, personalized evaluation of the cardiovascular system, and risk stratification for potential cardiovascular adverse events before initiating therapy are needed.
References
Beyer DC, McKeough T, Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 61(5): 1299–1305. [CrossRef] [PubMed]
Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, Roden DM, Moslehi JJ, Salem JE. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. Arch Cardiovasc Dis 2020;113(1):9-21. [CrossRef] [PubMed]
Cone EB, Reese S, Marchese M, Nabi J, McKay RR, Kilbridge KL, Trinh QD. Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study. EClinicalMedicine 2021; 36:100887. [CrossRef] [PubMed]
Connolly RM, Carducci MA, Antonarakis ES. Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl 2012;14(2):177-86. [CrossRef] [PubMed]
Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo A, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 2019; 22(1): 24–38.[CrossRef] [PubMed]
Culig Z. Molecular mechanisms of enzalutamide resistance in prostate cancer. Curr Mol Biol Rep 2017;3(4):230–5. [CrossRef] [PubMed]
Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020; 31(2): 171–90. [CrossRef] [PubMed]
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005. [CrossRef] [PubMed]
Fizazi K, Tran N, Fein L. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686–700. [CrossRef] [PubMed]
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al.: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378(26): 2465-74. [CrossRef] [PubMed]
Janssen. ZYTIGA (abiraterone acetate): highlights of prescribing information Food and Drug Administration 2018; Available from: URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210308s000lbl.pdf
Kumar A, Reddy A, Sekar A. Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events. Cardiooncology 2023; 9(1):9. [CrossRef] [PubMed]
Lacovelli R, Ciccarese C, Bria E, Romano M, Fantinell E, Bimbatti D, et al. The cardiovascular toxicity of Abiraterone and Enzalutamide in prostate cancer. Clin Genitourin Cancer 2018;16(3):e645–53. [CrossRef] [PubMed]
Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono SJ, Chowdhury S, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 2015; 16(5): 509-21. [CrossRef] [PubMed]
Mohler JL, Antonarakis ES. NCCN guidelines updates: management of prostate cancer. J Natl Compr Canc Netw 2019;17(5.5):583–6. [CrossRef] [PubMed]
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol 2016;34(18):2098–106. [CrossRef] [PubMed]
Pfizer. XTANDI (enzalutamide): highlights of prescribing information. Food and Drug Administration 2019; Available from: URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf
Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol 2019;9:801 [CrossRef] [PubMed]
Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin M, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110(7):1493–500. [CrossRef] [PubMed]
Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al. Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13): 1070–80. [CrossRef] [PubMed]
Shrestha B, Gouli S, Shrestha A. Abstract 16180: Cardiovascular adverse events associated with androgen receptor-targeted therapy used in the treatment of prostate cancer (abstract). Circulation 2020; 142:A16180 [CrossRef] [PubMed]
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Cancer Stat Facts: Prostate Cancer, Aggregated With State, Total U.S. (2018-2023) , National Cancer Institute, DCCPS, Surveillance Research Program, released February 2025. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
Wilk M, Waśko-Grabowska A, Szmit S. Cardiovascular Complications of Prostate Cancer Treatment. Front Pharmacol 2020;11:555475. [CrossRef] [PubMed]
Živković-Perišić S, Miljuš D, Jovanović V. Registration of malignant diseases in estimating global cancer burden. Glasnik javnog zdravlja 2021; 95(1):73-84.
